We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery).
- Authors
TOMÁS-VELÁZQUEZ, Alejandra; SANMARTIN-JIMÉNEZ, Onofre; R. GARCÉS, Joan; RODRÍGUEZ-PRIETO, Manuel A.; RUIZ-SALAS, Verónica; DE EUSEBIO-MURILLO, Esther; MIÑANO-MEDRANO, Román; ESCUTIA-MUÑOZ, Begoña; FLÓREZ-MENÉNDEZ, Ángeles; ARTOLA-IGARZA, Juan L.; ALFARO-RUBIO, Alberto; GIL, Pilar; DELGADOJIMÉNEZ, Yolanda; SÁNCHEZ-SCHMIDT, Julia M.; ALLENDE-MARKIXANA, Irati; ALONSO-PACHECO, María L.; GARCÍA-BRACAMONTE, Beatriz; DE LA CUEVA-DOBAO, Pablo; NAVARRO-TEJEDOR, Raquel; CIUDAD-BLANCO, Cristina
- Abstract
Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the "real-life" results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patientyears for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1-1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3-6.1), being constant over time (0-5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.
- Subjects
SQUAMOUS cell carcinoma; MOHS surgery; BASAL cell carcinoma; OLDER patients; IMMUNOCOMPROMISED patients
- Publication
Acta Dermato-Venereologica, 2021, Vol 101, Issue 11, p1
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/actadv.v101.544